Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.600
+0.090 (5.96%)
Mar 4, 2026, 4:00 PM EST - Market closed
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
Developing Curative Therapeutics for Patients | 52.30M | 44.76M | 17.20M | 243.00K |
Developing Curative Therapeutics for Patients Growth | 16.84% | 160.21% | 6978.19% | - |
| 52.30M | 44.76M | 17.20M | 243.00K |
| 16.84% | 160.21% | 6978.19% | - |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
| 52.30M | 44.76M | 17.20M | 243.00K |
| 16.84% | 160.21% | 6978.19% | - |
| 52.30M | 44.76M | 17.20M | 243.00K |
| 16.84% | 160.21% | 6978.19% | - |
Source: S&P Global Market Intelligence.
